NEW DEVELOPMENTS

Home > Blogs > Online First/Online Only > ONLINE FIRST: Pancreatic Cancer: Gemcitabine Plus Nab-Paclit...

Online First/Online Only Articles/items published ahead of print or only online.

Monday, January 28, 2013 ONLINE FIRST: Pancreatic Cancer: Gemcitabine Plus Nab-Paclitaxel Prolongs Survival in Patients with Metastatic Disease BY RABIYA S. TUMA, PHD SAN FRANCISCO -- Patients with metastatic pancreatic cancer now have another option for treatment, researchers reported here at the Gastrointestinal Cancers Symposium. In a Phase III randomized controlled trial, patients treated with nab-paclitaxel plus gemcitabine had a median overall survival of 8.5 months, compared with 6.7 months for patients receiving gemcitabine alone (Abstract LBA148).